Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML).

Authors

Lindsay Wilde, Thomas Jefferson University HospitalsFollow
Jillian Cooper, Thomas Jefferson UniversityFollow
Zi-Xuan Wang, Thomas Jefferson UniversityFollow
Jinglan Liu, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-4-2019

Comments

This article is the author’s final published version in Frontiers in Oncology, Volume 9, October 2019, Article number 1016.

The published version is available at https://doi.org/10.3389/fonc.2019.01016. Copyright © Wilde et al.

Abstract

t(8;21)(q22;q22) is present in ~5–10% of patients with de novo acute myeloid leukemia (AML) and is associated with a better overall prognosis. Variants of the t(8;21) have been described in the literature, however, their clinical and prognostic significance has not been well-characterized. Molecular profiling of these cases has not previously been reported but may be useful in better defining the prognosis of this subset of patients. We present two cases of variant t(8;21) AML including clinical, cytogenetic, and molecular data.

Recommended Citation

Wilde, Lindsay; Cooper, Jillian; Wang, Zi-Xuan; and Liu, Jinglan, "Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)." (2019). Department of Medical Oncology Faculty Papers. Paper 101.
https://jdc.jefferson.edu/medoncfp/101

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

31681569

Language

English